Literature DB >> 29593039

Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo.

Carolina Garrido1,2, Maria Abad-Fernandez1,3, Marina Tuyishime4, Justin J Pollara4, Guido Ferrari4, Natalia Soriano-Sarabia1,2, David M Margolis5,2,3,6.   

Abstract

Current efforts toward human immunodeficiency virus (HIV) eradication include approaches to augment immune recognition and elimination of persistently infected cells following latency reversal. Natural killer (NK) cells, the main effectors of the innate immune system, recognize and clear targets using different mechanisms than CD8+ T cells, offering an alternative or complementary approach for HIV clearance strategies. We assessed the impact of interleukin 15 (IL-15) treatment on NK cell function and the potential for stimulated NK cells to clear the HIV reservoir. We measured NK cell receptor expression, antibody-dependent cell-mediated cytotoxicity (ADCC), cytotoxicity, interferon gamma (IFN-γ) production, and antiviral activity in autologous HIV replication systems. All NK cell functions were uniformly improved by IL-15, and, more importantly, IL-15-treated NK cells were able to clear latently HIV-infected cells after exposure to vorinostat, a clinically relevant latency-reversing agent. We also demonstrate that NK cells from HIV-infected individuals aviremic on antiretroviral therapy can be efficiently stimulated with IL-15. Our work opens a promising line of investigation leading to future immunotherapies to clear persistent HIV infection using NK cells.IMPORTANCE In the search for an HIV cure, strategies to enhance immune function to allow recognition and clearance of HIV-infected cells following latency reversal are being evaluated. Natural killer (NK) cells possess characteristics that can be exploited for immunotherapy against persistent HIV infection. We demonstrate that NK cells from HIV-positive donors can be strongly stimulated with IL-15, improving their antiviral and cytotoxic potential and, more importantly, clearing HIV-infected cells after latency reversal with a clinically relevant drug. Our results encourage further investigation to design NK cell-based immunotherapies to achieve HIV eradication.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  ADCC; HIV; HIV eradication; IL-15; NK cell; SAHA; VOR; human immunodeficiency virus; immune function; immunotherapy; interleukins; kick and kill; latency reversal; natural killer cells; shock and kill; vorinostat

Mesh:

Substances:

Year:  2018        PMID: 29593039      PMCID: PMC5974478          DOI: 10.1128/JVI.00235-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.

Authors:  Peter R Rhode; Jack O Egan; Wenxin Xu; Hao Hong; Gabriela M Webb; Xiaoyue Chen; Bai Liu; Xiaoyun Zhu; Jinghai Wen; Lijing You; Lin Kong; Ana C Edwards; Kaiping Han; Sixiang Shi; Sarah Alter; Jonah B Sacha; Emily K Jeng; Weibo Cai; Hing C Wong
Journal:  Cancer Immunol Res       Date:  2015-10-28       Impact factor: 11.151

Review 2.  Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

Authors:  Thomas A Rasmussen; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

Review 3.  Preclinical shock strategies to reactivate latent HIV-1: an update.

Authors:  Gilles Darcis; Benoît Van Driessche; Carine Van Lint
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

4.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

5.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors:  V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

Review 6.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

7.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.

Authors:  Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

8.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Authors:  Kai Deng; Mihaela Pertea; Anthony Rongvaux; Leyao Wang; Christine M Durand; Gabriel Ghiaur; Jun Lai; Holly L McHugh; Haiping Hao; Hao Zhang; Joseph B Margolick; Cagan Gurer; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Steven G Deeks; Till Strowig; Priti Kumar; Janet D Siliciano; Steven L Salzberg; Richard A Flavell; Liang Shan; Robert F Siliciano
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

9.  HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function.

Authors:  Carolina Garrido; Adam M Spivak; Natalia Soriano-Sarabia; Mary Ann Checkley; Edward Barker; Jonathan Karn; Vicente Planelles; David M Margolis
Journal:  Front Immunol       Date:  2016-09-21       Impact factor: 7.561

10.  Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors.

Authors:  Ilona Hromadnikova; Petra Pirkova; Lucie Sedlackova
Journal:  Mediators Inflamm       Date:  2013-02-17       Impact factor: 4.711

View more
  47 in total

1.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.

Authors:  Carolina Garrido; Martin Tolstrup; Ole S Søgaard; Thomas A Rasmussen; Brigitte Allard; Natalia Soriano-Sarabia; Nancie M Archin; David M Margolis
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

Review 3.  Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics?

Authors:  Daniel R Ram; Cordelia Manickam; Olivier Lucar; Spandan V Shah; R Keith Reeves
Journal:  J Leukoc Biol       Date:  2019-02-07       Impact factor: 4.962

4.  γδ T cells: an immunotherapeutic approach for HIV cure strategies.

Authors:  Carolina Garrido; Matthew L Clohosey; Chloe P Whitworth; Michael Hudgens; David M Margolis; Natalia Soriano-Sarabia
Journal:  JCI Insight       Date:  2018-06-21

5.  Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.

Authors:  Marina Tuyishime; Carolina Garrido; Shalini Jha; Matt Moeser; Dieter Mielke; Celia LaBranche; David Montefiori; Barton F Haynes; Sarah Joseph; David M Margolis; Guido Ferrari
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 6.  Curing HIV: Seeking to Target and Clear Persistent Infection.

Authors:  David M Margolis; Nancie M Archin; Myron S Cohen; Joseph J Eron; Guido Ferrari; J Victor Garcia; Cynthia L Gay; Nilu Goonetilleke; Sarah B Joseph; Ronald Swanstrom; Anne-Marie W Turner; Angela Wahl
Journal:  Cell       Date:  2020-03-26       Impact factor: 41.582

7.  HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Authors:  Julia A Sung; Shabnum Patel; Matthew L Clohosey; Lauren Roesch; Tamara Tripic; JoAnn D Kuruc; Nancie Archin; Patrick J Hanley; C Russell Cruz; Nilu Goonetilleke; Joseph J Eron; Clio M Rooney; Cynthia L Gay; Catherine M Bollard; David M Margolis
Journal:  Mol Ther       Date:  2018-09-21       Impact factor: 11.454

8.  Role of IL-15 Signaling in the Pathogenesis of Simian Immunodeficiency Virus Infection in Rhesus Macaques.

Authors:  Afam A Okoye; Maren Q DeGottardi; Yoshinori Fukazawa; Mukta Vaidya; Chike O Abana; Audrie L Konfe; Devin N Fachko; Derick M Duell; He Li; Richard Lum; Lina Gao; Byung S Park; Rebecca L Skalsky; Anne D Lewis; Michael K Axthelm; Jeffrey D Lifson; Scott W Wong; Louis J Picker
Journal:  J Immunol       Date:  2019-10-25       Impact factor: 5.422

Review 9.  Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.

Authors:  Evan Rossignol; Galit Alter; Boris Julg
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

10.  Altered Cervical Mucosal Gene Expression and Lower Interleukin 15 Levels in Women With Schistosoma haematobium Infection but Not in Women With Schistosoma mansoni Infection.

Authors:  Kathryn M Dupnik; Myung Hee Lee; Pallavi Mishra; Mary Juliet Reust; Soledad Colombe; Syeda Razia Haider; Benjamin Yao; Kaitlin Vick; Tuo Zhang; Jenny Xiang; Donald Miyaye; Ruth Magawa; Eric Lyimo; Crispin Mukerebe; Julius Mngara; Samuel E Kalluvya; Claudia J de Dood; Govert J van Dam; Paul L A M Corstjens; Jennifer A Downs
Journal:  J Infect Dis       Date:  2019-05-05       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.